349 related articles for article (PubMed ID: 32273057)
1. Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk.
Gajanana D; Rogers T; Weintraub WS; Kolm P; Iantorno M; Khalid N; Chen Y; Shlofmitz E; Khan JM; Musallam A; Ben-Dor I; Satler LF; Zhang C; Torguson R; Waksman R
Am J Cardiol; 2020 Jun; 125(11):1631-1637. PubMed ID: 32273057
[TBL] [Abstract][Full Text] [Related]
2. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry.
Sorrentino S; Sartori S; Baber U; Claessen BE; Giustino G; Chandrasekhar J; Chandiramani R; Cohen DJ; Henry TD; Guedeney P; Ariti C; Dangas G; Gibson CM; Krucoff MW; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Urban P; Mehran R
Circ Cardiovasc Interv; 2020 Apr; 13(4):e008226. PubMed ID: 32216472
[TBL] [Abstract][Full Text] [Related]
3. Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.
Chichareon P; Modolo R; Kerkmeijer L; Tomaniak M; Kogame N; Takahashi K; Chang CC; Komiyama H; Moccetti T; Talwar S; Colombo A; Maillard L; Barlis P; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Valgimigli M; Windecker S; Onuma Y; Mehran R; Serruys PW
JAMA Cardiol; 2020 Jan; 5(1):21-29. PubMed ID: 31693078
[TBL] [Abstract][Full Text] [Related]
4. Validation of DAPT score for prolonged dual antiplatelet therapy in patients with acute myocardial infarction.
Veron-Esquivel D; Batiz-Armenta F; Cazares-Diazleal AC; Oviedo-Moguel S; Jarvio-Fernandez SM; Arce-Gonzalez JM; Ivey-Miranda JB
Hellenic J Cardiol; 2019; 60(5):296-302. PubMed ID: 29807194
[TBL] [Abstract][Full Text] [Related]
5. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.
Costa F; Van Klaveren D; Feres F; James S; Räber L; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
J Am Coll Cardiol; 2019 Feb; 73(7):741-754. PubMed ID: 30784667
[TBL] [Abstract][Full Text] [Related]
6. Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
Wang HY; Cai ZX; Yin D; Yang YJ; Song WH; Dou KF
Am J Cardiol; 2021 Mar; 142():14-24. PubMed ID: 33285091
[TBL] [Abstract][Full Text] [Related]
7. Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI.
Wang HY; Dou KF; Yin D; Zhang D; Gao RL; Yang YJ
BMC Cardiovasc Disord; 2020 Jul; 20(1):313. PubMed ID: 32611318
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
[TBL] [Abstract][Full Text] [Related]
9. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI.
Chichareon P; Modolo R; Kawashima H; Takahashi K; Kogame N; Chang CC; Tomaniak M; Ono M; Walsh S; Suryapranata H; Cotton J; Koning R; Akin I; Kukreja N; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW
JACC Cardiovasc Interv; 2020 Mar; 13(5):634-646. PubMed ID: 32139222
[TBL] [Abstract][Full Text] [Related]
10. Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline.
Wang HY; Dou KF; Wang Y; Yin D; Xu B; Gao RL
Cardiovasc Drugs Ther; 2020 Oct; 34(5):663-675. PubMed ID: 32601780
[TBL] [Abstract][Full Text] [Related]
11. Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Valgimigli M; Cao D; Angiolillo DJ; Bangalore S; Bhatt DL; Ge J; Hermiller J; Makkar RR; Neumann FJ; Saito S; Picon H; Toelg R; Maksoud A; Chehab BM; Choi JW; Campo G; De la Torre Hernandez JM; Kunadian V; Sardella G; Thiele H; Varenne O; Vranckx P; Windecker S; Zhou Y; Krucoff MW; Ruster K; Zheng Y; Mehran R;
J Am Coll Cardiol; 2021 Nov; 78(21):2060-2072. PubMed ID: 34794687
[TBL] [Abstract][Full Text] [Related]
12. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.
Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Cohen DJ; Steg PG; Cannon CP; Apruzzese PK; D'Agostino RB; Massaro JM; Mauri L;
JAMA Cardiol; 2017 May; 2(5):478-487. PubMed ID: 28297015
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Yeh RW; Secemsky EA; Kereiakes DJ; Normand SL; Gershlick AH; Cohen DJ; Spertus JA; Steg PG; Cutlip DE; Rinaldi MJ; Camenzind E; Wijns W; Apruzzese PK; Song Y; Massaro JM; Mauri L;
JAMA; 2016 Apr; 315(16):1735-49. PubMed ID: 27022822
[TBL] [Abstract][Full Text] [Related]
14. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
[TBL] [Abstract][Full Text] [Related]
15. High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.
Zocca P; Kok MM; van der Heijden LC; van Houwelingen KG; Hartmann M; de Man FHAF; Stoel MG; Louwerenburg JHW; Knottnerus IL; Linssen GCM; Doggen CJM; von Birgelen C
Int J Cardiol; 2018 Oct; 268():11-17. PubMed ID: 29801763
[TBL] [Abstract][Full Text] [Related]
16. Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention.
Wang HY; Dou KF; Yin D; Xu B; Zhang D; Gao RL
Am J Cardiol; 2020 Oct; 133():61-70. PubMed ID: 32811654
[TBL] [Abstract][Full Text] [Related]
17. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
[TBL] [Abstract][Full Text] [Related]
18. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Camaro C; Damen SA; Brouwer MA; Kedhi E; Lee SW; Verdoia M; Barbieri L; Rognoni A; van T Hof AW; Ligtenberg E; de Boer MJ; Suryapranata H; De Luca G
Am Heart J; 2016 Aug; 178():37-44. PubMed ID: 27502850
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.
Costa F; Valgimigli M; Steg PG; Bhatt DL; Hohnloser SH; Ten Berg JM; Miede C; Nordaby M; Lip GYH; Oldgren J; Cannon CP
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):216-226. PubMed ID: 33258897
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
Mauri L; Kirtane AJ; Windecker S; Yeh RW; Dauerman HL; Price MJ; Christen T; Allocco DJ; Meredith IT; Kereiakes DJ
Am Heart J; 2018 Nov; 205():110-117. PubMed ID: 30218844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
